Immunotherapy in Hispanic patients with advanced non-small cell lung cancer: A real-world data

e21094 Background: Nivolumab is a human programmed death receptor-1 (PD-1) blocking antibody, used as treatment option in patients with advanced non-small cell lung cancer (NSCLC). We assessed the nivolumab efficacy in terms of survival and response to treatment as second- or third-line therapy in p...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 40; no. 16_suppl; p. e21094
Main Authors:	Lujan, Mauricio, Lema, Mauricio, Preciado, Beatriz, Lema, Camila, Egurrola, Jorge, Cardona Zorrilla, Andres Felipe, Gonzalez, Diego Mauricio, Mantilla, William Armando, Pino, Luis, Rojas, Gustavo, Gomez-Abreo, Diego Andres, Munevar, Isabel, Manneh, Raimundo, Manneh Kopp, Ray, Lobaton, Jose F., Calle, Esteban, Borras, Mariana, Triana, Ivan Camilo, Pineda, Mateo, Moran Ortio, Diego
Format:	Journal Article
Language:	English
Published:	01-06-2022
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	e21094 Background: Nivolumab is a human programmed death receptor-1 (PD-1) blocking antibody, used as treatment option in patients with advanced non-small cell lung cancer (NSCLC). We assessed the nivolumab efficacy in terms of survival and response to treatment as second- or third-line therapy in patients with advanced NSCLC. Methods: This is a multicentric observational study. Data of patients with advanced NSCLC who received nivolumab as second (2L) or third-line (3L) treatment were analyzed retrospectively. Information regarding patient demographics and clinical backgrounds, treatment patterns from diagnosis to post-nivolumab treatment, effectiveness, and safety of nivolumab treatment were collected. The outcomes evaluated were overall survival (OS), progression-free survival (PFS), and objective reponse rate to treatment (ORR). OS and PFS were estimated with the Kaplan-Meier method. Statistical analysis was carried out using SPSS version 21.0. Results: Eleven centers distributed across the country (Colombia) participated. Data from 178 patients were included. The median follow-up was 26.8 months (IQR 20.3 - 40.4). Women represented 51.7% of the population, and the median age was 63 years (IQR 56-72 years). Nivolumab was commonly used as a 2L treatment. The ORR with nivolumab as 2L treatment was 21.0%. The median PFS and OS were 5.5 months (95%CI: 4.5 – 6.5) and 12.4 months (95%CI: 10.8 – 14.0), respectively. In 3L the ORR with nivolumab was 15.0%. The overall incidence of adverse events was 1.7%. Conclusions: Nivolumab effectiveness and safety in this scenario was consistent with than reported by previous trials and other real world data.
ISSN:	0732-183X 1527-7755
DOI:	10.1200/JCO.2022.40.16_suppl.e21094